New! Search for patents from more than 100 countries including Australia, Brazil, Sweden and more

WO2006110728A3 - Immunogenic cmv tegument aggregates - Google Patents

Immunogenic cmv tegument aggregates Download PDF

Info

Publication number
WO2006110728A3
WO2006110728A3 PCT/US2006/013451 US2006013451W WO2006110728A3 WO 2006110728 A3 WO2006110728 A3 WO 2006110728A3 US 2006013451 W US2006013451 W US 2006013451W WO 2006110728 A3 WO2006110728 A3 WO 2006110728A3
Authority
WO
WIPO (PCT)
Prior art keywords
tegument aggregates
invention provides
present invention
aggregates
cmv
Prior art date
Application number
PCT/US2006/013451
Other languages
French (fr)
Other versions
WO2006110728A2 (en
Inventor
Earl R Kern
Mark Neal Prichard
William J Britt
Original Assignee
Uab Research Foundation
Earl R Kern
Mark Neal Prichard
William J Britt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US67026205P priority Critical
Priority to US60/670,262 priority
Application filed by Uab Research Foundation, Earl R Kern, Mark Neal Prichard, William J Britt filed Critical Uab Research Foundation
Publication of WO2006110728A2 publication Critical patent/WO2006110728A2/en
Publication of WO2006110728A3 publication Critical patent/WO2006110728A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/21Retroviridae, e.g. equine infectious anemia virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/245Herpetoviridae, e.g. herpes simplex virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/385Haptens or antigens, bound to carriers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541Mucosal route
    • A61K2039/543Mucosal route intranasal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6075Viral proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/64Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA Viruses
    • C12N2710/00011MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA Viruses dsDNA Viruses
    • C12N2710/16011Herpesviridae
    • C12N2710/16111Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA Viruses
    • C12N2710/00011MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA Viruses dsDNA Viruses
    • C12N2710/16011Herpesviridae
    • C12N2710/16111Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse Transcribing RNA Viruses
    • C12N2740/00011Reverse Transcribing RNA Viruses
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16111Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse Transcribing RNA Viruses
    • C12N2740/00011Reverse Transcribing RNA Viruses
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16111Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

The present invention provides for cytomegalovirus protein tegument aggregates, pharmaceutical compositions, and the use thereof. The present invention provides for methods for anti-viral drug screening, production of CMV antigenic proteins, recombinant protein expression, immunogenic compounds such as CMV tegument aggregates with or without additional haptens, and vaccines useful for raising an immune response in an animal.
PCT/US2006/013451 2005-04-12 2006-04-11 Immunogenic cmv tegument aggregates WO2006110728A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US67026205P true 2005-04-12 2005-04-12
US60/670,262 2005-04-12

Publications (2)

Publication Number Publication Date
WO2006110728A2 WO2006110728A2 (en) 2006-10-19
WO2006110728A3 true WO2006110728A3 (en) 2007-12-06

Family

ID=37087624

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/013451 WO2006110728A2 (en) 2005-04-12 2006-04-11 Immunogenic cmv tegument aggregates

Country Status (1)

Country Link
WO (1) WO2006110728A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010068850A1 (en) 2008-12-12 2010-06-17 Georgetown University Methods of diagnosing and treating cancer
WO2010127180A2 (en) 2009-04-30 2010-11-04 University Of Rochester Dc-stamp antibodies
EP2496697B1 (en) 2009-11-06 2017-04-12 Howard Hughes Medical Institute Genetically encoded calcium indicators and methods of use
JP2014531896A (en) 2011-08-30 2014-12-04 ザ ユーエービー リサーチ ファンデーション Tuberculosis porins and toxins and related method
US9719992B2 (en) 2011-10-07 2017-08-01 Howard Hughes Medical Institute Genetically encoded biosensors
US20180153976A1 (en) * 2015-06-18 2018-06-07 Vaximm Ag Novel cmv pp65 targeting dna vaccine for cancer immunotherapy

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020156251A1 (en) * 1996-12-13 2002-10-24 Eric Prieur Fusion protein comprising the whole or part of the pp65 protein of human cmv, useable in particular for preparing a vaccine
US20030165522A1 (en) * 2000-03-23 2003-09-04 Zaia John A. Protein kinase deficient, immunologically active CMVpp65 mutants

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020156251A1 (en) * 1996-12-13 2002-10-24 Eric Prieur Fusion protein comprising the whole or part of the pp65 protein of human cmv, useable in particular for preparing a vaccine
US20030165522A1 (en) * 2000-03-23 2003-09-04 Zaia John A. Protein kinase deficient, immunologically active CMVpp65 mutants

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ADAIR ET AL.: "The products of human cytomegalovirus genes UL23, UL24, Ul43 and US22 are tegument components", JOURNAL OF GENERAL VIROLOGY, vol. 83, 2002, pages 1315 - 1324, XP008091914 *
PRICHARD ET AL.: "Human Cytomegalovirus UL97 Kinase Is Required for the Normal Intranuclear Distribution of pp65 and Virion Morphogenesis", JOURNAL OF VIROLOGY, vol. 79, no. 24, 2005, pages 15494 - 15502, XP008092465 *
SEVERI ET AL.: "Human cytomegalovirus nuclear and cytoplasmic dense bodies", J. ARCH. VIROL., vol. 123, no. 1-2, March 1992 (1992-03-01), pages 193 - 207, XP008091384 *

Also Published As

Publication number Publication date
WO2006110728A2 (en) 2006-10-19

Similar Documents

Publication Publication Date Title
WO2004030608A3 (en) Nanoemulsion vaccines
WO2002072636A8 (en) Crystals of whole antibodies and fragments thereof and methods for making and using them
WO2004003147A3 (en) Cngh0004 polypeptides, antibodies, compositions, methods and uses
WO2009025300A1 (en) Peptide capable of binding to immunoglobulin
WO2004024090A3 (en) Immunogens and corresponding antibodies specific for high molecular weight aggregation intermediates common to amyloids formed from proteins of differing sequence
WO2005019258A3 (en) Compositions and methods for the treatment of immune related diseases
WO2006041933A3 (en) Improved vaccines
WO2006133089A3 (en) Improved human interferon molecules and their uses
Fernández et al. Conformational and thermal stability improvements for the large-scale production of yeast-derived rabbit hemorrhagic disease virus-like particles as multipurpose vaccine
WO2009147248A3 (en) Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
MXPA05003413A (en) Use of the gk-1 peptide for potentiating the immune response induced by the influenza vaccine.
WO2006014292A3 (en) Oral vaccine for borrelia
WO2007022341A3 (en) Isolated soy protein having high molecular weight protein fractions and low molecular weight protein fractions
Wiwanitkit Cutaneous hypersensitivity in dengue infection and explanation of its pathogenesis by allergenicity assessment
WO2006038923A3 (en) Aryl substituted imidazonaphthyridines
WO2006031560A3 (en) Process for concentration of antibodies and therapeutic products thereof
WO2005019200A3 (en) Aryl piperidine derivatives as vla-1 integrin antagonists and uses thereof
WO2004024067A3 (en) Codon-optimized polynucleotide-based vaccines against bacillus anthracis infection
WO2005009378A3 (en) Polypeptides for inducing a protective immune response against staphylococcus aureus
TWI522466B (en) Recombinant antigen gene, recombinant antigen protein and subunit vaccine composition having the same against infection of porcine circovirus type 2
Lázaro et al. CAPSID PROTEINS: EVIDENCES ABOUT THE PROTECTIVE ROLE OF CELL-MEDIATED IMMUNITY AGAINST DENGUE
IL194550A (en) Isolated antibody or fragment thereof that binds to human protein tyrosine phosphatase beta, pharmaceutical compositions containing the same and uses thereof
WO2000076540A3 (en) Streptococcus pneumoniae proteins and vaccines
WO2006020430A8 (en) Novel composition and methods for the treatment of immune related disease
WO2003024480A3 (en) In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase in:

Ref country code: DE

NENP Non-entry into the national phase in:

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06749735

Country of ref document: EP

Kind code of ref document: A2